AbZelectPRO: Enhanced Cell Line Development

At BioProcess International Europe 2025, our Sr. Manager of Cell Line Development, Blanca San Miguel, presented a poster focused on our integrated CLD platform AbZelectPRO.

Abstract 

Our fully integrated AbZelectPRO platform enables the rapid delivery of stable, high-producing cell lines for complex biologics or bioconjugates. AbZelectPRO combines our CHO-K1 mammalian cell line with ProteoNic’s 2G UNic® premium vector technology and a tailored, optimized process to boost expression levels and generate fast-doubling, higher-producing, stable cell lines, expressing up to 8 g/L of product.

As a result, the AbZelectPRO platform supports the efficient and stable production of antibodies and more difficult-to-express proteins such as fusion proteins, bi-specifics, vaccines and other novel modalities. Backed by the extensive experience of Abzena’s experts in developing biologic therapeutics, which are supported by Abzena’s comprehensive analytics portfolio, the AbZelectPRO platform simplifies the IND application process and delivers client therapeutic proteins successfully to clinical phases. In addition, the platform enables activities such as downstream method development and formulation to be removed from the CLD critical path by using Early Material Generation from Stable Pools, which can also be run stand-alone as part of the Abzena offer.

Poster Authors include:

Blanca San Miguel, Oscar Swindley, Nathan Courtier, Kean Huedepohl, Ned Swift, Miles Wellington, Sophie Douglas, Noah Collins, Elizabeth Willows, Tania Fisher, Kalpana Wood, Tanya Knight, Beata Blaszczyk, Nicole Wakes, Brett Verstak